AnaptysBio Q2 net loss $39.8M; imsidolimab Phase 3 enrollment complete

ANAPTYSBIO, INC

2023-Q2 EPS reported -$3.08 revenue$4,834,000

Q2 net loss $39.8M ($1.50/sh) vs $32.6M ($1.15) YoY; six-month loss $84.1M ($3.08/sh).
Completed enrollment of GEMINI-1 Phase 3 for imsidolimab in GPP; top-line data expected Q4 2023.
Cash and investments $488.7M at June 30; updated year-end 2023 guidance $380-395M; runway through 2026.
Initiating global Phase 2b for rosnilimab in RA in Q3 2023; second Phase 2 trial by year-end.
Daniel Faga appointed permanent president and CEO; new SAB members added.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ANAPTYSBIO, INC reported financial results for second quarter ended June 30, 2023.

Period: second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 7, 2023, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three and six months ended June 30, 2023.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

ANAPTYSBIO, INC filing history →

Source: SEC EDGAR

accession 0001370053-23-000048

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.